KUVATRIS THERAPEUTICS, INC. Research and Development Expense
KUVATRIS THERAPEUTICS, INC. reported Research and Development Expense of $116.93 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2026-01-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-01-14
- KUVATRIS THERAPEUTICS, INC. research and development expense for the quarter ending 2024-09-30 was $116.93K, a 93.97% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. research and development expense for the quarter ending 2024-06-30 was $1.51M, a 156.27% increase year-over-year.
- KUVATRIS THERAPEUTICS, INC. research and development expense for the quarter ending 2024-03-31 was $392.81K, a 76.55% increase year-over-year.
- KUVATRIS THERAPEUTICS, INC. research and development expense for the quarter ending 2023-12-31 was $1.16M, a 389.22% increase year-over-year.
- KUVATRIS THERAPEUTICS, INC. research and development expense for fiscal 2023 was $3.91M, a 119.02% increase from fiscal 2022.
- KUVATRIS THERAPEUTICS, INC. research and development expense for fiscal 2022 was $1.79M, a 19.65% decline from fiscal 2021.
- KUVATRIS THERAPEUTICS, INC. research and development expense for fiscal 2021 was $2.22M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $116.93K 10-Q · filed 2026-01-14 | $1.63M derived: sum of 2 quarters · filed 2026-01-14 | $2.02M 10-Q · filed 2026-01-14 | $3.18M derived: sum of 4 quarters · filed 2026-01-14 |
| 2024-06-30 | $1.51M 10-Q · filed 2024-09-20 | $1.90M 10-Q · filed 2024-09-20 | $3.07M derived: sum of 3 quarters · filed 2024-09-20 | $5.01M derived: sum of 4 quarters · filed 2026-01-14 |
| 2024-03-31 | $392.81K 10-Q · filed 2024-05-13 | $1.56M derived: sum of 2 quarters · filed 2024-05-13 | $3.50M derived: sum of 3 quarters · filed 2026-01-14 | $4.09M derived: sum of 4 quarters · filed 2026-01-14 |
| 2023-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $3.10M derived: sum of 2 quarters · filed 2026-01-14 | $3.69M derived: sum of 3 quarters · filed 2026-01-14 | $3.91M 10-K · filed 2024-03-11 |
| 2023-09-30 | $1.94M 10-Q · filed 2026-01-14 | $2.53M derived: sum of 2 quarters · filed 2026-01-14 | $2.75M 10-Q · filed 2026-01-14 | $2.99M derived: sum of 4 quarters · filed 2026-01-14 |
| 2023-06-30 | $589.03K 10-Q · filed 2024-09-20 | $811.52K 10-Q · filed 2024-09-20 | $1.05M derived: sum of 3 quarters · filed 2024-09-20 | $1.38M derived: sum of 4 quarters · filed 2024-09-20 |
| 2023-03-31 | $222.49K 10-Q · filed 2024-05-13 | $460.58K derived: sum of 2 quarters · filed 2024-05-13 | $787.85K derived: sum of 3 quarters · filed 2024-05-13 | $939.27K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $238.09K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $565.36K derived: sum of 2 quarters · filed 2024-03-11 | $716.78K derived: sum of 3 quarters · filed 2024-03-11 | $1.79M 10-K · filed 2024-03-11 |
| 2022-09-30 | $327.27K 10-Q · filed 2023-11-16 | $478.69K derived: sum of 2 quarters · filed 2023-11-16 | $1.55M 10-Q · filed 2023-11-16 | $2.02M derived: sum of 4 quarters · filed 2023-11-16 |
| 2022-06-30 | $151.43K 10-Q · filed 2023-08-09 | $1.22M 10-Q · filed 2023-08-09 | $1.69M derived: sum of 3 quarters · filed 2023-08-09 | $2.13M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.07M 10-Q · filed 2023-05-15 | $1.54M derived: sum of 2 quarters · filed 2023-05-15 | $1.98M derived: sum of 3 quarters · filed 2023-05-15 | $2.87M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $469.13K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $906.69K derived: sum of 2 quarters · filed 2023-03-30 | $1.80M derived: sum of 3 quarters · filed 2023-03-30 | $2.22M 10-K · filed 2023-03-30 |
| 2021-09-30 | $437.56K 10-Q · filed 2022-11-14 | $1.33M derived: sum of 2 quarters · filed 2022-11-14 | $1.76M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $889.91K 10-Q · filed 2022-09-30 | $1.32M 10-Q · filed 2022-09-30 |